Quantitative evaluation of skin disorders caused by molecular targeted agents - prediction of skin disorders and clinical application: a prospective clinical study

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K16419
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Iwate Medical University
• Principal Investigator: Takahashi Hiroaki 岩手医科大学, 薬学部, 助教 (90815995)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 抗EGFR抗体薬 / ざ瘡様皮疹 / 経皮水分蒸散量 / 皮膚障害 / 皮膚状態

Outline of Final Research Achievements

In the present study, transepidermal water loss was quantitatively evaluated in patients with colorectal cancer scheduled to receive the anti-epidermal growth factor receptor (EGFR) antibody for the first time as cancer drug therapy, and the relationship between skin condition changes and skin disorders caused by the anti-EGFR antibody was prospectively examined. The results suggest that skin disorders associated with the anti-EGFR antibody therapy may become more severe in patients who are taller and heavier at the start of administration or experience high transepidermal water loss in the second week of administration.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

本研究の結果から、抗EGFR抗体薬の投与開始時に身長や体重が大きい患者では保湿剤やステロイド軟膏を予防的に使用する等、早期からの対処が可能になる。また、投与2週目に経皮水分蒸散量が高い患者では、皮膚障害対策を強化することで、皮膚障害をコントロールして治療を継続することが出来るかもしれない。これらの結果が、患者QOLの向上、さらには生存率の延長に繋がる可能性がある。